The first instalment of two-part article looking at people behind the most important events and trends in pharma, biotech and wider world of healthcare in 2015.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh